Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer

Not Applicable

Recruiting

• Conditions: Lung Cancer

• Registration Number: NCT06742021
• Lead Sponsor: Yunnan Cancer Hospital

Brief Summary

This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-11-11
• Status Verified: 2024-12
• Study First Submitted: 2024-12-15
• Study First Submitted QC: 2024-12-15
• Last Update Submitted: 2024-12-15
• Study First Posted: 2024-12-19
• Last Update Posted: 2024-12-19
• Primary Completion: 2026-07-31
• Study Completion: 2026-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 195

Inclusion Criteria

1. Tumor size greater than 2 cm
2. Age between 18 and 75 years

Exclusion Criteria

1. Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.)
2. Allergy to gadolinium contrast agents
3. Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Tumor treatment response evaluation	within one week before treatment and two weeks after treatment completion	This study aims to evaluate tumor treatment response using the RECIST V1.1 criteria, based on CT images taken within one week before treatment and two weeks after treatment completion.

Trial Locations

Locations (1)

Yunnan Cancer Hospital; 🇨🇳 Kunming, Yunnan, China